WooGene B&G Past Earnings Performance
Past criteria checks 2/6
WooGene B&G has been growing earnings at an average annual rate of 24.2%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 13.1% per year. WooGene B&G's return on equity is 2%, and it has net margins of 0.3%.
Key information
24.2%
Earnings growth rate
26.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 13.1% |
| Return on equity | 2.0% |
| Net Margin | 0.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How WooGene B&G makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 59,959 | 167 | 12,001 | 1,028 |
| 31 Mar 24 | 60,624 | -688 | 11,353 | 1,056 |
| 31 Dec 23 | 57,919 | -1,184 | 10,821 | 907 |
| 30 Sep 23 | 49,120 | -9 | 8,821 | 683 |
| 30 Jun 23 | 47,802 | 894 | 8,309 | 474 |
| 31 Mar 23 | 44,878 | 179 | 7,595 | 336 |
| 31 Dec 22 | 43,703 | 850 | 6,661 | 270 |
| 30 Sep 22 | 47,578 | -1,351 | 6,756 | 289 |
| 30 Jun 22 | 45,964 | -1,446 | 6,359 | 284 |
| 31 Mar 22 | 41,535 | -828 | 6,319 | 327 |
| 31 Dec 21 | 39,347 | -2,258 | 6,427 | 305 |
| 30 Sep 21 | 34,790 | -3,550 | 5,732 | 248 |
| 30 Jun 21 | 34,516 | -2,082 | 5,901 | 201 |
| 31 Mar 21 | 38,287 | -4,243 | 6,154 | 148 |
| 31 Dec 20 | 39,524 | -3,030 | 6,246 | 105 |
| 30 Sep 20 | 42,980 | -2,224 | 6,670 | 98 |
| 30 Jun 20 | 40,141 | -2,925 | 6,302 | 42 |
| 31 Mar 20 | 36,154 | -522 | 5,870 | 15 |
| 31 Dec 19 | 29,656 | -333 | 5,560 | 59 |
| 30 Sep 19 | 27,211 | 349 | 5,557 | 110 |
| 30 Jun 19 | 27,524 | -1,602 | 5,599 | 104 |
| 31 Mar 19 | 28,208 | -4,843 | 5,616 | 116 |
| 31 Dec 18 | 28,131 | -6,632 | 5,766 | 106 |
| 31 Dec 17 | 22,934 | -4,190 | 6,866 | 513 |
Quality Earnings: A018620 has high quality earnings.
Growing Profit Margin: A018620's current net profit margins (0.3%) are lower than last year (1.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A018620 has become profitable over the past 5 years, growing earnings by 24.2% per year.
Accelerating Growth: A018620's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A018620 had negative earnings growth (-81.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22%).
Return on Equity
High ROE: A018620's Return on Equity (2%) is considered low.